EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

New Treatment Options for MASLD Patients with Type 2 Diabetes

Andrea Mega iD, A.I.G.O. (Italian Association of Hospital Gastroenterologists) and C.L.E.O. (Italian Association of Hospital Hepatologists), Chiara Turri, Luca Marzi iD, Marco Dauriz iD, Rodolfo Sacco iD, Annarosa Floreani, Cristina Stasi iD

Life · 02.02.2026 · 16 (2) · 254

DOI: 10.3390/life16020254 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life, online erschienen am 02.02.2026. Verfasst von Andrea Mega und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, South-Tyrolean Healthcare System (SABES-ASDAA), Bolzano General Hospital, 39100 Bolzano, Italy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is defined by hepatic steatosis in individuals with at least one cardiometabolic risk factor, most commonly type 2 diabetes mellitus (T2DM). People with non-alcoholic fatty liver disease, even without other metabolic factors, have a higher risk of T2DM. MASLD includes isolated liver steatosis, metabolic dysfunction-associated steatohepatitis, fibrosis, cirrhosis, and MASH-related hepatocellular carcinoma. MASLD patients are also at a higher risk of developing T2DM than the general population. International guidelines recommend a stepwise approach for identifying those at high risk of fibrotic progression, using the FIB-4 index for initial screening, followed by transient elastography. The link between MASLD and T2DM is notable due to shared pathophysiological mechanisms, some of which are reversible with treatment used in T2DM. Many new glucose-lowering drugs have also proven effective in improving anthropometric and metabolic parameters, as well as the stage of hepatic steatosis and fibrosis. Recent evidence suggests that GLP-1RAs and SGLT2is have beneficial effects in MASLD patients with T2DM. Specifically, GLP-1RAs improve hepatic insulin signaling, modulate lipid metabolism, reduce inflammation, and decrease hepatocyte oxidative stress. European guidelines recommend resmetirom as a MASH-targeted therapy, if locally approved, for adults with non-cirrhotic MASH and significant liver fibrosis (stage ≥ 2) and GLP-1RAs in MASH, including compensated cirrhosis, but they should be used for their respective indications, such as T2DM and obesity. Given the post-COVID burden of MASLD and its high risk of liver fibrosis progression among T2DM patients, this review specifically provides an overview of the complex relationship between MASLD and T2DM. Additionally, it examines current understanding of liver fibrosis evaluation and the effects of novel treatment options, with a particular focus on glucose-lowering therapies and their effects on necroinflammation, hepatic fat accumulation, and fibrosis progression in patients with MASLD and T2DM.

Schlagwörter

Stichwörter der Autor:innen

cirrhosisfibrosisglucagon-like peptide-1 agonistsmetabolic dysfunction-associated steatohepatitismetabolic dysfunction-associated steatotic liver diseaseoral glucose-lowering agentsodium-glucose co-transporter 2 inhibitorstransient elastographytype 2 diabetes

Autor:innen und Institutionen

  • Department of Gastroenterology, South-Tyrolean Healthcare System (SABES-ASDAA), Bolzano General Hospital, 39100 Bolzano, Italy.
  • Section of Endocrinology and Diabetes, Department of Internal Medicine, South-Tyrolean Healthcare System (SABES-ASDAA), Bolzano General Hospital, 39100 Bolzano, Italy.
  • Gastroenterology and Digestive Endoscopy Unit, Department of Surgical and Medical Sciences, University of Foggia, Viale Pinto 1, 71122 Foggia, Italy.
  • University of Padova, 35128 Padua, Italy.
  • IRCCS Negrar, 37024 Verona, Italy.
  • Department of Life Science, Health and Health Professions, Link Campus University, 00165 Roma, Italy.

ORCID-Profile: Andrea Mega, Luca Marzi, Marco Dauriz, Rodolfo Sacco, Cristina Stasi

Zitieren

APA

Mega, A., A.I.G.O. (Italian Association of Hospital Gastroenterologists) and C.L.E.O. (Italian Association of Hospital Hepatologists), Turri, C., Marzi, L., Dauriz, M., Sacco, R., Floreani, A., & Stasi, C. (2026). New Treatment Options for MASLD Patients with Type 2 Diabetes. Life, 16(2), 254. https://doi.org/10.3390/life16020254

Vancouver

Mega A, A.I.G.O. (Italian Association of Hospital Gastroenterologists) and C.L.E.O. (Italian Association of Hospital Hepatologists), Turri C, Marzi L, Dauriz M, Sacco R, et al. New Treatment Options for MASLD Patients with Type 2 Diabetes. Life. 2026;16(2):254. doi:10.3390/life16020254

BibTeX
@article{Mega2026,
  author = {Mega, Andrea and A.I.G.O. (Italian Association of Hospital Gastroenterologists) and C.L.E.O. (Italian Association of Hospital Hepatologists), A.I.G.O. (Italian Association of Hospital Gastroenterologists) and C.L.E.O. (Italian Association of Hospital Hepatologists) and Turri, Chiara and Marzi, Luca and Dauriz, Marco and Sacco, Rodolfo and Floreani, Annarosa and Stasi, Cristina},
  title = {New Treatment Options for MASLD Patients with Type 2 Diabetes},
  journal = {Life},
  year = {2026},
  volume = {16},
  number = {2},
  pages = {254},
  doi = {10.3390/life16020254}
}
Kostenlos starten →